Table 2.
Baseline characteristics according to dose groups
| Characteristics | Group 1, 5 mg Correct, n = 294 | Group 2, 2.5 mg Correct, n = 102 | Group 3, 2.5 mg Incorrect, n = 166 | Group 2 vs Group 3, P Value |
|---|---|---|---|---|
| Female sex | 107 (36.4) | 55 (53.9) | 74 (44.6) | 0.137 |
| Male sex | 187 (63.6) | 47 (46.1) | 92 (55.4) | 0.137 |
| Mean age, y | 66.9 ± 11.4 | 82.0 ± 7.1 | 76.5 ± 7.9 | <0.0001 |
| ≤74 | 199 (67.7) | 13 (12.7) | 53 (31.9) | |
| 75–79 | 72 (24.5) | 10 (9.8) | 57 (34.4) | |
| ≥80 | 23 (7.8) | 79 (77.5) | 56 (33.7) | |
| Weight, kg | 87.6 ± 19.6 | 74.8 ± 17.3 | 82.2 ± 15.5 | 0.00038 |
| ≥66 | 262 (89.1) | 66 (64.7) | 142 (85.6) | |
| 61–65 | 18 (6.1) | 7 (6.9) | 14 (8.4) | |
| ≤60 | 14 (4.8) | 29 (28.4) | 10 (6.0) | |
| sCr, μmol/l | 89.8 ± 25.8 | 173.4 ± 70.1 | 107.6 ± 31.1 | <0.0001 |
| ≤119 | 278 (94.6) | 20 (19.6) | 119 (71.7) | |
| 120–132 | 11 (3.7) | 2 (2.0) | 17 (10.2) | |
| ≥133 | 5 (1.7) | 80 (78.4) | 30 (18.1) | |
| eGFR, mL/min/1.73 m2 | 73.7 ± 20.3 | 32.0 ± 15.5 | 55.3 ± 18.0 | <0.0001 |
| BMI, kg/m2 | 29.7 ± 11.6 | 27.5 ± 5.3 | 29.0 ± 5.2 | 0.019 |
| Interventions | ||||
| TAVR | 7 (2.4) | 33 (32.4) | 54 (32.5) | 0.976 |
| Ablation | 74 (25.2) | 0 (0.0) | 4 (2.4) | 0.114 |
| Cardioversion | 82 (27.9) | 9 (8.8) | 17 (10.2) | 0.703 |
| Stent/PTCA | 6 (2.0) | 17 (16.7) | 34 (20.5) | 0.44 |
| Pacemaker | 34 (11.6) | 18 (17.6) | 23 (13.9) | 0.402 |
| OAC naïve | 226 (76.9) | 73 (71.6) | 131 (78.9) | 0.171 |
| OAC previously received | 68 (23.1) | 29 (28.4) | 35 (21.1) | 0.171 |
| SAPT | 22 (7.5) | 54 (52.9) | 87 (52.4) | 0.615 |
| DAPT | 2 (0.7) | 0 (0.0) | 10 (6.0) | 0.012 |
| Prior bleeding episodes | 13 (4.4) | 12 (11.8) | 21 (12.7) | 0.83 |
| CHA2DS2‐VASc score | 2.9 ± 1.8 | 5.0 ± 1.3 | 4.4 ± 1.4 | 0.001 |
| CHF | 52 (17.7) | 34 (33.3) | 47 (28.3) | 0.385 |
| HTN | 241 (82.0) | 99 (97.1) | 157 (94.6) | 0.34 |
| DM | 75 (25.5) | 43 (42.2) | 77 (46.4) | 0.499 |
| Stroke/TIA | 22 (7.5) | 18 (17.6) | 15 (9.0) | 0.037 |
| Vascular disease | 63 (21.4) | 57 (55.9) | 80 (48.2) | 0.221 |
Abbreviations: BMI, body mass index; CHA2DS2‐VASc, CHF, HTN, age > 75 y, DM, stroke/TIA, vascular disease, age 65–74 y, sex category (female); CHF, congestive heart failure; DAPT, dual antiplatelet therapy; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HTN, hypertension; OAC, oral anticoagulation; PTCA, percutaneous transluminal coronary angioplasty; SAPT, single antiplatelet therapy; sCr, serum creatinine; SD, standard deviation; TAVR, transcatheter aortic valve replacement; TIA, transient ischemic attack.
Data are presented as n (%) or mean ± SD.